Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

A phase I trial (NCT03447314; 204686) evaluated the safety and efficacy of GSK1795091, a Toll‐like receptor 4 (TLR4) agonist, in combination with immunotherapy (GSK3174998 [anti‐OX40 monoclonal antibody], GSK3359609 [anti‐ICOS monoclonal antibody], or pembrolizumab) in patients with solid tumors. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Steeghs, Neeltje, Hansen, Aaron R., Hanna, Glenn J., Garralda, Elena, Park, Haeseong, Strauss, James, Adam, Michael, Campbell, Gossett, Carver, Jennifer, Easton, Rachael, Mays, Katherine, Skrdla, Peter, Struemper, Herbert, Washburn, Michael L., Matheny, Christopher, Piha‐Paul, Sarina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652439/
https://www.ncbi.nlm.nih.gov/pubmed/36097345
http://dx.doi.org/10.1111/cts.13387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652439/
https://www.ncbi.nlm.nih.gov/pubmed/36097345
http://dx.doi.org/10.1111/cts.13387

Ejemplares similares